3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

79.65 -2.70 ( -3.28% ) 4:02 2/22/18 Pricing delayed 20 minutes

Volume 340,376

Recent News

See All
February 22, 2018 Nevro Reports Fourth Quarter and Full Year 2017 Financial Results and Provides 2018 Outlook
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months and full year ended December 31, 2017 . 2017 Accomplishment & Highlights: Achieved revenue of $326.7 million for the full year 2017, an increase of 43%, as reported, over the prior year U.S. revenue of $263.5 million for 2017, an increase of 52% over the prior year International revenue of $63.2 million for 2017, an increase of 13% in constant currency and 15% on an as-reported basis, both over the prior year Achieved positive EBITDA and operating cash flow for each of the third and fourth quarters of 2017, excluding litigation expense Received CE Mark for next generation Senza II Received CE Mark for Senza I Conditional Full Body MRI Initiated Randomized Controlled Trials (RCT) in two new indications Presented positive clinical trial results during the 16 th Annual Pain Medicine...
February 8, 2018 Nevro to Report Operating Results for the Fourth Quarter and Full Year 2017
Nevro to Host Conference Call on Thursday, February 22, 2018 at 1:30 p.m. PT / 4:30 p.m. ET Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the fourth quarter and full year of 2017 after market close on Thursday, February 22, 2018 . Company management will host a conference call beginning at 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on Thursday, February 22, 2018 . Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers, or (734) 385-2616 for international callers (Conference ID: 2584428), or from the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro...
January 12, 2018 Nevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Company's Senza Spinal Cord Stimulation Systems Delivering HF10™ Therapy at NANS Annual Meeting
Non-Opioid Treatment Option Offers Profound, Paresthesia-Free Pain Relief for Growing Numbers of Patients Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of HF10 ™ therapy for patients with chronic pain at the 21 st Annual Meeting of the North American Neuromodulation Society (NANS) taking place through January 14 in Las Vegas . "Our large and growing body of clinical evidence supports the use of HF10 therapy for patients suffering from debilitating chronic pain and looking for alternatives to opioids," said Rami Elghandour, President and CEO of Nevro. "With a number of studies initiated in a variety of pain areas and indications, we are uniquely positioned to deliver on the promise of neuromodulation by applying our best-in-class therapy to treat a broad array of challenging disease states.  In today's environment,...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.